Xing Feng1, Lucheng Zhu1,2, Xiaoling Xiong3, Hong Jiang1, Zhibing Wu2, Wen Meng1, Yasi Xu1, Shirong Zhang1, Shenglin Ma1. 1. a Hangzhou First People's Hospital, Nanjing Medical University , Hangzhou , PR China. 2. b Hangzhou Cancer Hospital , Hangzhou , PR China. 3. c Sir Run Run Shaw Hospital Affiliated with School of Medicine , Zhejiang University , Hangzhou , PR China.
Abstract
BACKGROUND: Patients with malignant pleural effusions (MPEs) have limited life expectancy. This study aims to investigate the feasibility of intrapleural perfusion with hyperthermic chemotherapy (IPHC) under video-assisted thoracoscopic surgery on MPE patients. METHODS: MPE patients were enrolled in the study and treated with IPHC. The treatment response was classified as complete response (CR, no re-accumulation of pleural fluid for 4 weeks), partial response (PR, re-accumulation above the post-IPHC level but below the pre-IPHC level for four weeks), no response (NR; re-accumulation or above the pre-IPHC level). The change of Karnofsky performance score (KPS) and tumour markers were also recorded. Follow-up was done every two weeks during first month and monthly thereafter until death. RESULTS: Eighty patients included 46 males and 34 females were included in the study. The total response rate was 100%, with 71.3% of CR and 28.7% of PR. The KPS scores were significantly elevated and the level of tumour markers in pleural effusion were dramatically decreased after IPHC. The median survival was 16.8 months ranged from 2.1 to 67.4 months. One-year and two-year survival rates were 82.5% and 23.8%, respectively. There were no serious clinical compilations during IPHC treatment. CONCLUSIONS: IPHC is a safety, effective and promising approach for MPE patients. It provides well survival benefit and minor toxicities.
BACKGROUND:Patients with malignant pleural effusions (MPEs) have limited life expectancy. This study aims to investigate the feasibility of intrapleural perfusion with hyperthermic chemotherapy (IPHC) under video-assisted thoracoscopic surgery on MPE patients. METHODS: MPE patients were enrolled in the study and treated with IPHC. The treatment response was classified as complete response (CR, no re-accumulation of pleural fluid for 4 weeks), partial response (PR, re-accumulation above the post-IPHC level but below the pre-IPHC level for four weeks), no response (NR; re-accumulation or above the pre-IPHC level). The change of Karnofsky performance score (KPS) and tumour markers were also recorded. Follow-up was done every two weeks during first month and monthly thereafter until death. RESULTS: Eighty patients included 46 males and 34 females were included in the study. The total response rate was 100%, with 71.3% of CR and 28.7% of PR. The KPS scores were significantly elevated and the level of tumour markers in pleural effusion were dramatically decreased after IPHC. The median survival was 16.8 months ranged from 2.1 to 67.4 months. One-year and two-year survival rates were 82.5% and 23.8%, respectively. There were no serious clinical compilations during IPHC treatment. CONCLUSIONS:IPHC is a safety, effective and promising approach for MPE patients. It provides well survival benefit and minor toxicities.
Entities:
Keywords:
Intrapleural perfusion with hyperthermic chemotherapy; hyperthermia; malignant pleural effusion; pleural disease; video-assisted thoracoscopic surgery
Authors: Ioannis Karampinis; Anna Dionysopoulou; Christian Galata; Katrin Almstedt; Maurizio Grilli; Annette Hasenburg; Eric D Roessner Journal: Thorac Cancer Date: 2022-02-22 Impact factor: 3.500